Maravai LifeSciences (NASDAQ:MRVI) Upgraded by UBS Group to Hold Rating

UBS Group upgraded shares of Maravai LifeSciences (NASDAQ:MRVI) to a hold rating in a research report released on Wednesday morning,Zacks reports.

Several other equities analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. Wells Fargo & Company lifted their price objective on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $6.83.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $6.53 on Wednesday. The stock has a fifty day moving average price of $6.86 and a 200-day moving average price of $5.05. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -12.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. Maravai LifeSciences has a fifty-two week low of $2.55 and a fifty-two week high of $9.42.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%.The business had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. As a group, equities analysts anticipate that Maravai LifeSciences will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. WINTON GROUP Ltd acquired a new position in Maravai LifeSciences in the 2nd quarter worth about $604,000. Engineers Gate Manager LP bought a new stake in shares of Maravai LifeSciences during the second quarter worth about $487,000. NewEdge Advisors LLC bought a new stake in shares of Maravai LifeSciences during the second quarter worth about $207,000. Squarepoint Ops LLC acquired a new position in shares of Maravai LifeSciences in the second quarter valued at approximately $128,000. Finally, California State Teachers Retirement System raised its holdings in Maravai LifeSciences by 61.5% in the 2nd quarter. California State Teachers Retirement System now owns 9,553 shares of the company’s stock valued at $60,000 after buying an additional 3,639 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.